Five things for pharma marketers to know: Tuesday, September 20, 2016



1. GlaxoSmithKline announced Tuesday that Emma Walmsley (pictured) will succeed Andrew Witty as CEO. Walmsley is currently the head of GSK's consumer healthcare business, which includes brands such as Excedrin, Flonase, and TheraFlu.

2. The FDA approved the first drug for Duchenne muscular dystrophy. The agency's decision to approve Sarepta Therapeutics' eteplirsen comes after months of support from vocal patient communities who called for the approval. Sarepta said the drug will cost $300,000 on average per year. (WaPo)

3. Sanofi filed a lawsuit against Merck for allegedly infringing on the patent of its long-acting insulin, Lantus. The French drugmaker said Merck violated as many as 10 patents, including for Lantus' delivery device, which is called the SoloStar. (WSJ)

4. Allergan said it will buy Tobira Therapeutics — a developer of treatments for nonalcoholic steatohepatitis, or NASH — in a deal worth up to $1.7 billion. Just last week, Allergan agreed to buy Vitae Pharmaceuticals for $639 million.

5. Regeneron Pharmaceuticals and Teva Pharmaceutical Industries will co-develop and co-market an investigational pain drug, fasinumab, that if approved could be a non-addictive alternative to opioids. The drug is currently in trials and being tested as a potential reliever for osteoarthritis and chronic lower back pain. (Reuters)